Charles River Laboratories International Inc.
CRL | NYSE
$279.01
+$0.95 (+0.34%)
At close: Sep 21, 2026, 4:00 PM ET
$279.01
$0 (0.00%)
After-hours:
Sep 21, 2026, 5:55 PM ET
Company Profile
Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Birgit Girshick | CEO & Director |
| Glenn G. Coleman | Corporate Executive Vice President & Chief Financial Officer |
| Kerry Dailey | Corporate Senior VP & Chief Legal Officer |
| Mark Mintz | Corporate EVP, Chief Information Officer & Global Shared Services |
| Victoria L. Creamer | Corporate Executive Vice President & Chief People Officer |
| Amy Cianciaruso | Corporate Senior Vice President, Chief Communications Officer & Government Relations |
| Brian F. Bathgate | Corporate Senior Vice President of European Safety Assessment |
| Joseph W. LaPlume | Corporate Executive Vice President of Corporate Development & Strategy |
| Michael Gunnar Knell | Corporate Senior Vice President & Chief Accounting Officer |
| Todd Spencer | Corporate Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 27, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | 4 | Filing |
| Aug 11, 2026 | 4 | Filing |
| Aug 10, 2026 | 4 | Filing |
Charles River Laboratories International Inc.
| Country | United States |
| IPO Date | Jun 22, 2000 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 19,000 |
| CEO | Birgit Girshick |
Contact Details
251 Ballardvale Street Wilmington,
Massachusetts 01887 United States
Stock Details
| Ticker Symbol | CRL |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001100682 |
| CUSIP Number | 159864107 |
| ISIN Number | US1598641074 |
| SIC Code | 8731 |
Recent News
- 5 days ago / businesswire.comCharles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- 6 days ago / seekingalpha.comCharles River Laboratories International, Inc. (CRL) Presents at 2026 Global Healthcare Conference Transcript
- 8 days ago / seekingalpha.comCharles River Laboratories International, Inc. (CRL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 18 days ago / zacks.comCharles River (CRL) Up 10.5% Since Last Earnings Report: Can It Continue?
- 21 days ago / zacks.comIs This the Right Time to Add CRL Stock to Your Portfolio?
- 1 month ago / zacks.comCRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?
- 1 month ago / zacks.comCharles River Gains 88.6% in a Year: What's Driving the Rally?
- 1 month ago / defenseworld.netCharles River Laboratories International (NYSE:CRL) Sets New 52-Week High – Still a Buy?
- 1 month ago / zacks.comInternational Markets and Charles River (CRL): A Deep Dive for Investors
- 2 months ago / marketbeat.comCharles River Laboratories International Q2 Earnings Call Highlights
Add to Watchlist
Select watchlists to add or remove CRL